Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005
Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008
Effectiveness of empirical treatment of community acquired pneumonia requiring hospitalization Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006
Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008
The usage of laferon in treatment of patients with community acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 675s Year: 2007
Improving outcome in elderly patients with pneumonia Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006
Determinants of performance of indicators on antibiotic use in community-acquired pneumonia (CAP) at hospitals Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004
Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004
The efficiency of levofloxacin in the therapy of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 5s Year: 2006
A simple method for determining the time of conversion to oral antibiotic therapy in community-acquired pneumonia (CAP) Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001
Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009
Developing outcome-based guidelines in CAP and AECB Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005
Frequency of antibiotic resistance and outcomes in severe community acquired pneumonia due to Streptococcus pneumoniae Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009
Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013
Cost-efficacy analysis of cefixime switch therapy in the treatment of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006